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Inherited deficiencies or functional abnormalities of plasma substances  that par- 
ticipate in  blood coagulation have provided a  powerful tool for  identification and 
analysis of these plasma proteins on a  molecular basis. A  new deficiency associated 
with prolonged blood thromboplastin formation was described by Hathaway, Belhasen, 
and Hathaway in 1965  (1). The abnormality was inherited as an autosomal recessive 
and was identified in four of eleven siblings. The responsible factor differed from other 
proteins of the intrinsic coagulation pathway since mutual correction occurred when 
this plasma was mixed with plasma obtained from patients with known coagulation 
factor  deficiencies.  The  missing  principle  was  identified  by  the  surname  of  the 
propositus family and called Fletcher factor. 
Recently,  studies carried out with highly purified proteins of  the plasma kinin- 
forming system led to an unexpected observation. The protein prekallikrein developed, 
upon incubation with active Hageman factor, potent clot-accelerating activity in a 
partial thromboplastin test when rabbit plasma was used as substrate (2). A role for 
kallikrein in  coagulation  was  neither  anticipated  nor  easily explained.  When  the 
opportunity became available to study blood plasma from an individual with Fletcher 
factor  deficiency,  several  abnormalities,  in  addition  to  prolonged  thromboplastin 
formation, were identified in this plasma and each was corrected by addition of the 
kallikrein precursor. 
Materials and Methods 
Blood Plasma.--Platelet poor plasmas from normal individuals or from persons with estab- 
lished coagulation deficiencies were collected in acid citrate dextrose anticoagulant and stored 
at --70°C in 1-ml aliquots until used.  Dr. C. Abildgaard kindly supplied plasma from the 
patient with Fletcher factor deficiency. Dr.  S. I. Rapaport generously  gave plasma from 
patients with plasma thromboplastin antecedent  (PTA)  1 and plasma thromboplastin com- 
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ponent (PTC)  deficiencies.  Mrs. Gunda Hiatt, deficient in Hageman factor, donated her blood 
for these studies. 
Coagulation  Tests.--The  kaolin-activated  partial  thromomboplastin  test  performed  in 
plastic  10  >(  75 mm tubes was used  throughout. All dilutions were made in 0.15 M  NaCI 
buffered with 0.01 M  tris(hydroxymethyl)aminomethane (Tris-saline), pH 7.5.  Correction of 
deficient plasmas by normal plasma was studied by performing twofold dilutions of normal 
plasma with the deficient plasma as diluent. Calibrated capillary pipettes (Scientific Products 
Div., McGraw Park, Ill.) used for dilutions were siliconized (Siliclad; Clay Adams, Parsippany, 
N.J.). To 50 #1 of buffer was added 50 ~zl of plasma and 50 #1 of a mixture that contained in 
final concentration kaolin 5 mg/ml and cephalin 1:10 (Bell and Alton cephalin; Sigma Chemi- 
cal Co., St. Louis, Mo.). Mter incubation for 3 min, the mixture was recalcified with 0.05 M 
CaC12 50 #1 in Tris-saline. The time required for a  clot to form was  then  determined. All 
incubations were performed at 37°C. 
Purified Proteins.--The precursor of the enzyme kallikrein was prepared in highly purified 
form by methods described elsewhere (3) for rabbit preka]likrein. 
Human prekallikrein purification followed the same procedure with minor modifications.  2 
After chromatography on DEAE-Sephadex A-50 and carboxymethyl Sephadex C-50, the pool 
of prekallikrein was concentrated by ultrafiltration and electrophoresed in Pevikon (Pharmacia, 
Uppsala, Sweden) at 10 V/cm for 22 h at 4°C. Before use, the Pevikon was rinsed with hexa- 
dimethrine bromide 50 #g/ml (Po]ybrene; Aldrich Chemical Co., Inc., Milwaukee, Wis.) and 
washed with distilled water on a  Biichner funnel. The supporting granules were finally sus- 
pended in the electrophoresis buffer of citrate-phosphate, pH 6.2, ionic strength 0.04 relative 
salt concentration. The only protein known to contaminate the preparation of prekallikrein 
was 82-glycoprotein (I), determined by a specific antiserum obtained from Behring Diagnostics 
(Woodbury,  N.Y.).  The  two  substances  were  resolved  by  gradient  ultracentrifugation in 
sucrose 5-25% in Tris-saline buffer. 
Immunochemlcal Studies.--Anfiserum to human prekallikrein was a  gift of Behringwerke 
AG, Marburg-Lahn, West Germany. The antiserum was allowed to diffuse in agarose against 
highly purified prekallikrein. The antiserum was also absorbed with an equal volume of normal 
plasma or Fletcher factor-deficient plasma and tested similarly. 
Antiserum to human Hageman factor was supplied by Dr. C. G. Cochrane. It was absorbed 
with human Hageman factor-deficient plasma before use. 
Bradykinin  Generation.--Measurement  of kinin generation in plasma was performed with a 
uterine horn of a  150 g  Sprague Dawley rat injected 48 h  earlier with 75 #g of stilbestrol in 
mineral oil. To 50 pl of plasma in plastic tubes was added 50 #1 of Tris-saline buffer and 50 #1 
of kaolin, 10 mg/ml. The optimal time for measurement of kinin generation by a 50/A aliquot 
of this mixture occurred 3 rain after addition of kaolin. In an attempt to replace the deficiency 
in Fletcher factor plasma, known quantities of prekallikrein in Tris-saline were substituted for 
buffer. 
Formation of Permeability Factor PF/dil.--Tests for PF/dil formation followed the descrip- 
tion of Ratnoff and Miles (4).  20 #1 of plasma was diluted to 2 ml in sterile saline in a  new 
glass tube, covered with parafilm, and inverted 40 times each minute on a Lab Tek aliquot 
mixer (Miles Laboratories Inc., Kankakee, Ill.) for 15 min. A volume of 0.1 ml was injected 
into the skin of rabbits that had received intravenous injections of 10 mg of chlorpheniramine 
maleate (Schering Diagnostics, Port Reading, N.J.) and 3 ml of a 2.5% solution of Evans blue 
dye in saline. The reactions that developed were maximal at 10-15 rain. The animal was sacri- 
riced 30 min after the injections were begun and the diameter of bluing on the undersurface 
of the skin of the back was measured. Duplicate injections were performed from rump to neck 
or neck to rump to offset regional variabiliW that occurs in some animals. 
2 Wuepper, K. D., and  C.  G. Cochrane. Purification and characterization of human pre- 
kallikrein. Manuscript in preparation. KIRK  D.  WUEPPER  1347 
Plasmin  Activation by Kaolin.--A method for generation of fibrinolytic activity in dilute 
acidified plasma in the presence of kaolin has been described (5). Tris-saline buffer was used 
throughout. Briefly, 0.5 ml of plasma to which 0.25 ml of kaolin 8 mg/ml was added was 
brought to 10 ml with 0.01 M acetate buffer, pH 4.8. This resulted in the formation of a 
euglobulin precipitate. Mter incubation 60 min at 37°C, the kaolin and euglobulin were sedi- 
mented by centrifugation. They were dispersed in 0.5 ml of buffer and 0.2-ml aliquots were 
taken for duplicate tests and placed in an ice bath.  Human fibrinogen (Nutritional  Bio- 
chemicals Corp., Cleveland, Ohio) 4mg/ml  and  0.1 ml  bovine  thrombin  (Parke,  Davis 
and Co., Detroit, Mich.) 50 NIH U/ml were added. The tubes were transferred to an incu- 
bation bath at 37°C and inspected each minute for lysis. 
RESULTS 
Abnormal  Thromboplastin  Formation  and  Its  Correction  with  Plasma  or 
Prekallikrein.--When  Fletcher  factor-deficient  plasma  was  incubated  with 
kaolin  and  cephalin  for 3  min  and  recalcified,  coagulation  was  abnormally 
prolonged. Normal plasma, mixed with Fletcher factor-deficient plasma, fully 
corrected the prolonged clotting when added in final concentration of 2 %  or 
greater  (Fig.  1).  The  response was  dose  dependent  between  0.1  and  2%  of 
normal  plasma.  2 %  final  concentration  of Hageman factor-deficient plasma 
or  plasma  thromboplasfin  antecedent-deficient  plasma  fully  corrected  the 
abnormality of Fletcher factor-deficient plasma. 
When  highly purified human  or rabbit prekallikrein was added  to normal 
plasma or plasma deficient in  factor XII, factor XI,  factor IX,  or  Fletcher 
factor-deficient plasma  and  tested  by  the  kaolin-activated  partial  thrombo- 
plastin test,  only the Fletcher factor-deficient plasma was corrected (Fig.  2). 
Reconsfitution  of Fletcher  factor-deficient plasma by prekallikrein  was  dose 
dependent between 0.1 and 3/~g. 
The final step in purification of rabbit prekallikrein was block electrophoresis 
in Pevikon. When aliquots of fractions were tested for their ability to correct 
the  abnormal  thromboplastin test,  a  peak of activity was readily identified. 
This  peak  corresponded  exactly  to  fractions  that  developed  the  ability  to 
release  bradykinin  from plasma  or  hydrolyze benzoyl-L-arginine  ethyl  ester 
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FIG.  1.  Correction  of  abnormal  thromboplastin  formation  of  Fletcher  factor-deficient 
plasma  by  normal  plasma.  The  correction  of  Hageman  factor-deficient  or  PTA-deficient 
plasma by normal plasma is shown for comparison. 1348  PREKALLIKREIN  DEFICIENCY 
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FIO. 2.  Reconstitufion  by rabbit prekallikrein of abnormal  thromboplastin  formation  in 
Fletcher  factor (FF)-deficient plasma.  Plasmas  deficient in Hageman factor (XII), plasma 
thromboplastin  antecedent  (XI), Christmas  factor  (IX),  or normal  plasma  (N)  were un- 
affected by addition of preka]likrein. 
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FIG. 3.  Correction of Fletcher factor-deficient plasma by aliquots of fractions containing 
prekallikrein recovered from Pevikon block electrophoresis. Prekallikrein was identified by its 
ability  to generate kinin  (data not shown) or hydrolyze the synthetic  substrate  BAEe after 
activation. 
(BAEe)  upon  incubation  with  active  Hageman  factor  or  trypsin  (Fig.  3). 
Such fractions  contained  a  single protein  band  when  subjected  to analytical 
disk-gel electrophoresis at pH 9.3. 
Human  prekallikrein,  similarly  highly  purified,  behaved  in  an  identical 
manner. After the fourth step in purification, block electrophoresis in Pevikon, 
human prekallikrein  was contaminated only by/32-glycoprotein (type I)  (Fig. 
4).  When  the  two  substances  were  resolved  by sucrose gradient  ultracentri- KIRK  D.  WUEPPER  1349 
FIG. 4.  Electrophoresis of human prekallikrein in 10% acrylamide gels containing sodium 
dodecyl sulfate after block electrophoresis in Pevikon or after sucrose gradient ultracentrifuga- 
tion. 
fugation, only fractions containing prekallikrein corrected the abnormality in 
Fletcher factor-deficient plasma. 
Attempts  to  Generate Kinin  in  Fletcher Factor-Deficient  Plasma.--If  pre- 
kallikrein were the protein absent from Fletcher factor-deficient plasma, such 
plasma might be expected to be abnormal in tests for kinin generation. Ac- 
cordingly, plasma was incubated briefly with kaolin and an aliquot was added 
to a  rat uterine preparation in a  Schultz Dale apparatus. Normal plasma or 
PTA-deficient plasma readily released a  kinin upon such treatment. Fletcher 
factor-deficient plasma,  like Hageman factor-deficient plasma, failed to gen- 
erate kinin (Fig. 5). These two plasmas gave mutual correction, however, when 
they were mixed. When 4/zg of highly purified human prekallikrein was added 
to  the  Fletcher factor-deficient plasma,  the defect was  corrected.  Hageman 
factor-deficient plasma was unaffected by the addition of this plasma protein 
(Fig. 5). 
Immunochemical  Studies.--An  antiserum  to  human  prekallikrein  precipi- 
tated with the highly purified protein by double  diffusion in  agar.  Normal 
plasma absorbed out this antibody, whereas Fletcher factor-deficient plasma 
did not absorb the antibody to prekallikrein (Fig. 6). An antiserum to human 
Hageman factor gave a line of identity with antigens present in normal plasma 
or Fletcher factor-deficient plasma. The antigen in Hageman factor-deficient 
plasma was absent. 
PF/dil.--Normal  or  coagulation factor-deficient plasma  was  diluted,  in- 
cubated briefly in glass vessels,  and injected into the skin of rabbits.  PF/dil 
was  not formed in  Fletcher factor-deficient plasma  or in  Hageman  factor- 
deficient plasma (Table I). 
In  an  attempt  to  determine whether  the  presence  of  small  quantities of 
Hageman factor or prekallikrein would allow one to assign the function of 1350  PREKALLIKREIN DEFICIENCY 
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FIG. 5. Bioassay of kinin formation by human plasma in the presence of kaolin. Abbrevia- 
tions: B, bradykinin  in  nanograms; NP,  normal plasma;  XII, Hageman factor-deficient 
plasma; FF, Fletcher factor-deficient plasma; XI, PTA-deficient plasma; PK, human pre- 
kallikrein 4 pg; k, kaolin. 
FIG. 6.  Absence of prekallikrein antigen in Fletcher factor-deficient plasma. Wells 1 and 2 
contain human prekallikrein. Well b contains rabbit antibody to prekallikrein. This antibody 
was absorbed with normal plasma (well a) or Fletcher factor-deficient  plasma (well c). 
PF/dil to one of these proteins, mixtures of the two plasmas, each deficient in 
one of these proteins, were made and tested for PF/dil formation. As little as 
2 %  of either plasma gave nearly complete correction of the other (Table II). 
Plasmin Generation.--Studies  were conducted with dilute, acidified plasma in 
the presence of kaolin  to learn  whether prekallikrein  deficiency would  affect 
the  generation  of  a  fibrinolytic  enzyme.  Prekallikrein-deficient  plasma,  like 
Hageman  factor-deficient plasma,  was  abnormal  in  this  regard  (Table III). 
Mixtures  of the two plasmas resulted in full correction by as little as 5 %  of 
either plasma  (Table IV). The addition  of  1.7/~g of human prekallikrein  to 
Fletcher  factor-deficient plasma  corrected  the  abnormally long  lysis  time of KIRK  D. WUEPPER  1351 
TABLE  I 
Formation of PF/dil in Defined Plasmas 
Plasma source  Permeability  diameter* 
mm 
Normal plasma  12, 12, 11, 9.5 
Hageman factor deficient  3 (f), 4(f), 5 
Fletcher factor deficient  0, 3(f), 4.5 
PTA deficient  11, 11.5, 8 
Christmas factor deficient  10, 10.5, 9.5 
Saline  3(f), 5 
* f  refers to faint bluing. 
TABLE  II 
Reconstitution of PF/dil Activity in Hageman Factor or Fletcher Factor-Deficient Plasmas by 
Limiting Quantities of the Other Plasma 
Plasma in mixture* 
XII dp  FF dp 
Permeability  diameter~:  § 
Sahne 
°7  o  ~nm 
100  0  f, f, 3(f), 4(f) 
98  2  10, 9.5,  10, 9. 
75  25  11.5,  12, 12.5,  11.5 
50  50  12, 10.5,  12., 12. 
25  75  12.5,  12, 13, 11.5 
2  98  10, 9.5,  10, 9 
0  100  f, f, f, 3(f) 
f, 3(f) 
* Plasmas deficient in Hageman factor  (XII dp) or Fletcher factor  (FF dp) were mixed in 
proper proportion in plastic tubes, diluted  1:100 in sterile saline in glass tubes, inverted  15 
min, and 0.1 ml injected. 
:~ The injections were made from rump to neck on the right and from neck to rump on the 
left side of the animal. Results were read at 30 rain on the reflected skin. The results of dupli- 
cate injections recorded by two observers are given. 
§ f  means faint reaction with indistinct margins; 3 (f) means a 3 mm faint reaction. 
78 min to normal, 11 min. The ability of Hageman factor-deficient plasma to 
form plasmin was unaffected by addition of the  same  quantity of prekalli- 
krein. 
DISCUSSION 
Blood plasma from a  person with Fletcher factor deficiency was found to 
be abnormal in tests for thromboplastin formation, kinin generation, evolution 
of a  permeability globulin (PF/dil), or plasmin formation. Each of these ab- 
normalities has, at a prior time, been reported for individuals with Hageman 
trait  (4,  6-8).  In the studies reported here,  Fletcher factor-deficient plasma 1352  PREKALLIKREIN  DEFICIENCY 
TABLE III 
Kaolin-Induced  Euglobulin Lysis of Normal or Coagulation Factor-Deficlent  Plasmas 
Plasma source  Lysis time* 
m/~ 
Normal  12 
Hageman factor deficient  > 125 
Fletcher factor deficient  78 
PTA deficient  16 
Christmas factor deficient  13 
Buffer control  > 125 
* Mean of duplicate determinations, estimated to the nearest minute. 
TABLE IV 
Correction of Abnormal Plasmin Formation of Fletcher Factor-Deficient  Plasma by 
Mixing with Hageman Factor-Deficient  Plasma 
Plasma in mixture* 
XII dp  FF dp 
Lysis time:~ 
~O  ml~b 
100  0  >125 
98  2  38 
95  5  16 
50  50  11 
5  95  12 
2  98  36 
0  100  78 
* Plasmas deficient in Hageman factor (XII dp) or Fletcher factor (FF dp) were mixed in 
correct proportion and 0.5 ml used as described in Materials and Methods. 
Mean of duplicate determinations, estimated to the nearest minute. 
(but  not  Hageman  factor-deficient  plasma)  was  corrected  by  addition  of 
highly purified prekallikrein from human  or rabbit sources or by small quan- 
tities of Hageman  factor-deficient plasma. The  results argue strongly against 
an inhibitory substance as the cause of the multiple abnormalities in Fletcher 
factor-deficient plasma.  The  role  that  is played  by  Hageman  factor  or  pre- 
kallikrein is worthy of discussion. 
Three  lines  of  evidence  support  the  conclusion  that  the  abnormality  in 
Fletcher factor-deficient plasma represents an inherited deficiency of the plasma 
protein  prekallikrein.  First,  addition  of  prekallikrein  corrected  in  a  dose- 
dependent  fashion  the  abnormally  prolonged  formation  of  blood  thrombo- 
plastin  in  Fletcher factor  deficiency.  Control  plasmas  deficient in  Hageman 
factor,  PTA,  or  PTC  were  not  reconstituted  by  addition  of  prekallikrein. 
Secondly, bradykinin was not generated when Fletcher factor-deficient plasma 
was incubated with kaolin and tested by bioassay. This abnormality was also KIRK  D.  WUEPPER  1353 
reconstituted by  addition  of  prekallikrein.  Finally,  Fletcher factor-deficient 
plasma  appeared  to  lack prekallikrein  antigen that  was  present  in  normal 
plasma. The abnormal responses of Hageman factor-deficient plasma in tests 
for  thromboplastin generation or kinin formation were  not affected by  ad- 
dition of prekallikrein. 
This  abnormality  in  Fletcher  factor-deficient  plasma  presented  an  im- 
portant  opportunity  to  study the  role  of prekallikrein  in  the  formation of 
PF/dil. Fletcher factor-deficient plasma was as abnormal in the development 
of  this  permeability agent  as  Hageman factor deficiency (4).  Prekallikrein- 
deficient plasma had a  normal amount of Hageman factor by the reference 
plasma method and Hageman factor antigen was readily demonstrated. Hage- 
man factor per se acting alone in the absence of prekallikrein is  therefore in- 
capable of forming PF/dil. It was hoped that  by restricting the quantity of 
Hageman factor or prekallikrein in mixtures of the two deficient plasmas that 
one  might  identify one  of  these  proteins  as  PF/dil.  The  results  suggested 
otherwise.  Both  proteins  were  clearly  necessary  for  the  formation  of  this 
permeability agent.  Only 2 %  of  their normal  concentration in  plasma  was 
sufficient for PF/dil formation. The amount of Hageman factor or prekallikrein 
in such mixtures would be that present at a 1 : 5,000 dilution of plasma. Plasma 
at this concentration does not give reactions of permeability. Taken together, 
information at hand supports  the conclusion that both Hageman factor and 
prekallikrein are necessary, both possibly not sufficient, for the formation of 
PF/dil. 
Hageman factor has been known for some time to play a  role in formation 
of  a  fibrinolytic substance  (8,  10,  11). When  prekallikrein-deficient plasma 
was tested for its ability to form plasmin, dissolution of the clot was abnor- 
mally prolonged. Small quantities of either Hageman factor-deficient plasma 
or prekallikrein-deficient plasma corrected the other plasma fully. Experience 
in this laboratory has failed to give evidence that active Hageman factor or 
kallikrein cause lysis of fibrin clots directly. Nor do these enzymes cause direct 
activation of plasminogen. This suggests that another plasma protein of the 
plasma fibrinolytic system is activated by one of these enzymes. Evidence for a 
plasma  plasminogen proactivator  that is  activated by Hageman factor was 
recently described by Kaplan and Austen (12). 
The  clinical  reports  concerning  patients  with  Fletcher  factor  deficiency 
reveal  that these persons  have  no  trouble with hemostasis  (1).  This is not 
unlike the situation with Hageman factor deficiency. In tests of coagulation 
in vitro, the role of prekallikrein must be placed earlier than the activation 
of  plasma  thromboplastin  antecedent.  When  highly purified active  PTA  is 
tested  in  defined  plasmas,  it  accelerates  coagulation  of  Hageman  factor, 
Fletcher factor, and PTA-deficient plasmas (13). It did not cause acceleration 
of  coagulation  with  Christmas  factor-deficient plasma  (13).  There  is  now 1354  PREKALLIKREIN DEFICIENCY 
ample  evidence  that  Hageman  factor  in  its  activated  form  is  an  enzyme. 
This enzyme has been shown to activate prekallikrein (3) or precursor plasma 
thromboplastin  antecedent  (13)  by limited proteolysis.  Recent evidence has 
been presented that  catalytic amounts of kallikrein activate precursor Hage- 
man  factor  (14).  Taken  together,  these observations  suggest  that  Hageman 
factor and prekallikrein become activated together in a cyclical or cocatalytic 
fashion. When kaolin serves as the stimulus to activation of this system, normal 
amounts of prekallikrein in the absence of Hageman factor (Hageman factor- 
deficient plasma)  do not give normal  coagulation after prolonged incubation 
with kaolin.  On  the other hand,  normal amounts  of Hageman factor in  the 
absence of prekallikrein  (Fletcher factor-deficient plasma)  slowly  correct the 
coagulation abnormality upon prolonged incubation with kaolin (9). 
It is probably artificial to consider the plasma kinin-forming system and the 
intrinsic blood coagulation pathway separately. Since two of the  three com- 
ponents of the kinin system, i.e. Hageman factor and prekallikrein, are now 
known  to  participate  in  normal  blood thromboplastin  formation,  these  two 
systems  should  be  considered  to  be functionally and  fundamentally united. 
Prekallikrein is  a  plasma  protein whose presence is  required for the  normal 
function of the intrinsic coagulation pathway,  the generation of bradykinin, 
the formation of PF/dil, and the activation of plasmin under defined in vitro 
conditions. 
SUMMARY 
Blood plasma  obtained from an individual  with  abnormal  thromboplastin 
formation, due to deficiency of Fletcher factor, was fully corrected by 2 %  of 
normal, Hageman factor-  or PTA-deficient plasma.  It was also  reconstituted 
by addition of highly purified human or rabbit prekallikrein. The plasma failed 
to generate kinin upon exposure to kaolin, a defect which was also corrected by 
addition  of  prekallikrein.  Prekallikrein  antigen  was  not  detectable  in  this 
plasma. 
Fletcher factor-deficient plasma  did not  support the normal generation of 
PF/dil when dilute plasma was incubated in glass vessels and injected intra- 
cutaneously. Small quantities of Fletcher factor-deficient or Hageman factor- 
deficient plasma corrected the ability of the other to generate PF/dil. 
The formation of plasmin in dilute, acidified plasma incubated with kaolin 
was  also  abnormal  in  Fletcher  factor-deficient plasma.  Plasmin  generation 
was normalized by addition of prekallikrein or small  quantities of Hageman 
factor-deficient plasma. 
The data support the identity of Fletcher factor and prekallikrein. 
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